Literature DB >> 12237249

A new ligand for the urotensin II receptor.

Valeria Camarda1, Remo Guerrini, Evi Kostenis, Anna Rizzi, Girolamo Calò, Almut Hattenberger, Marina Zucchini, Severo Salvadori, Domenico Regoli.   

Abstract

The cyclic peptide human urotensin II (U-II) has been recently recognized as the endogenous ligand of an orphan GPCR, subsequently named the UT receptor. No synthetic ligands are available for investigating this novel peptide-receptor system. A novel UT receptor ligand, [Orn(8)]U-II, was synthesized and evaluated in calcium functional assays performed on HEK293 cells expressing the recombinant rat and human UT receptor and in the rat aorta bioassay. [Orn(8)]U-II behaves as a full agonist (pEC(50) approximately equal 8) at both human and rat UT receptors in the FlipR calcium assay eliciting similar maximal effects as the natural ligand U-II. On the contrary, in the rat aorta bioassay, [Orn(8)]U-II behaves as a competitive and selective antagonist (pA(2)=6.56) showing however a small but consistent residual agonist activity. It is therefore proposed that [Orn(8)]U-II is a partial agonist at UT receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237249      PMCID: PMC1573506          DOI: 10.1038/sj.bjp.0704895

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction.

Authors:  H P Nothacker; Z Wang; A M McNeill; Y Saito; S Merten; B O'Dowd; S P Duckles; O Civelli
Journal:  Nat Cell Biol       Date:  1999-10       Impact factor: 28.824

2.  Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Authors:  S A Douglas; A C Sulpizio; V Piercy; H M Sarau; R S Ames; N V Aiyar; E H Ohlstein; R N Willette
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 3.  Drug efficacy at G protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

Review 4.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

5.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Authors:  R S Ames; H M Sarau; J K Chambers; R N Willette; N V Aiyar; A M Romanic; C S Louden; J J Foley; C F Sauermelch; R W Coatney; Z Ao; J Disa; S D Holmes; J M Stadel; J D Martin; W S Liu; G I Glover; S Wilson; D E McNulty; C E Ellis; N A Elshourbagy; U Shabon; J J Trill; D W Hay; E H Ohlstein; D J Bergsma; S A Douglas
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

6.  Pharmacological characterisation of the first non-peptide bradykinin B2 receptor agonist FR 190997: an in vitro study on human, rabbit and pig vascular B2 receptors.

Authors:  A Rizzi; C Rizzi; S Amadesi; G Calo'; K Varani; N Inamura; D Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-10       Impact factor: 3.000

7.  Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.

Authors:  Valeria Camarda; Anna Rizzi; Girolamo Calò; Gabrielle Gendron; Stephan I Perron; Evi Kostenis; Paolo Zamboni; Francesco Mascoli; Domenico Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-11-20       Impact factor: 3.000

8.  Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

9.  Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

Authors:  Stefanie Flohr; Michael Kurz; Evi Kostenis; Alexandre Brkovich; Alain Fournier; Thomas Klabunde
Journal:  J Med Chem       Date:  2002-04-25       Impact factor: 7.446

Review 10.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

Authors:  S A Douglas; E H Ohlstein
Journal:  Trends Cardiovasc Med       Date:  2000-08       Impact factor: 6.677

View more
  13 in total

1.  A comparison of assay performance between the calcium mobilization and the dynamic mass redistribution technologies for the human urotensin receptor.

Authors:  Mi Young Lee; Jihye Mun; Jeong Hyun Lee; Sunghou Lee; Byung Ho Lee; Kwang-Seok Oh
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

2.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).

Authors:  Valeria Camarda; Martina Spagnol; Wei Song; Raffaella Vergura; Adelheid L Roth; Jonathan P Thompson; David J Rowbotham; Remo Guerrini; Erika Marzola; Severo Salvadori; Paolo Cavanni; Domenico Regoli; Stephen A Douglas; David G Lambert; Girolamo Calò
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 4.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-27       Impact factor: 3.000

5.  Urotensin II stimulates plasma extravasation in mice via UT receptor activation.

Authors:  Raffaella Vergura; Valeria Camarda; Anna Rizzi; Martina Spagnol; Remo Guerrini; Girolamo Calo'; Severo Salvadori; Domenico Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-23       Impact factor: 3.000

6.  Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Authors:  Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

7.  The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.

Authors:  Christopher L Herold; David J Behm; Peter T Buckley; James J Foley; William E Wixted; Henry M Sarau; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

8.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 9.  Role of urotensin II and its receptor in health and disease.

Authors:  John McDonald; Madura Batuwangala; David G Lambert
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

10.  Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.

Authors:  Riccardo Patacchini; Paolo Santicioli; Sandro Giuliani; Paolo Grieco; Ettore Novellino; Paolo Rovero; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2003-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.